Physician profile
Gerald Jay Bishop
NPI 1316913338
$307,095.35
in general payments reported to CMS, 2019-2025
7 companies · $8,915 in 2025
The $8,915 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $21K · 2021: $42K · 2022: $87K · 2023: $35K · 2024: $34K · 2025: $8,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $7,020 · Travel and Lodging: $4,307 · Food and Beverage: $1,645 · Education: $60.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,818.00 |
| Consulting Fee | $7,020.00 |
| Travel and Lodging | $4,307.01 |
| Food and Beverage | $1,645.40 |
| Education | $60.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $297,708.09 | 2019-2024 | Xarelto |
| Amgen INC. | $8,915.08 | 2024-2025 | Repatha |
| Janssen Scientific Affairs, LLC | $350.55 | 2019-2023 | Xarelto |
| Csl Behring | $83.40 | 2025 | Kcentra |
| Tactile Systems Technology INC | $16.13 | 2024 | Flexitouch Plus, Entre Plus |
| E.R. Squibb & Sons, L.L.C. | $12.61 | 2021 | |
| Organogenesis INC. | $9.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.